source
- STAT+: Latigo reports mid-stage success for would-be rival to Vertex’s pain drug JournavxLatigo Biotherapeutics published positive data for an acute-pain drug meant to rival a Vertex medicine already on the marketSTAT · 34m ago↗ source
- Two biotechs sign reverse mergers to advance I&I drug, BTK inhibitorA biotech with a bispecific antibody from China and a little-known San Diego startup with a BTK inhibitor from Gossamer Bio have each signed reverse mergers to take their experimental medicines ont…Endpoints · 6h ago↗ source
- STAT+: Why benchmarking clinical LLMs from OpenEvidence, Doximity is complicatedIn this edition of AI Prognosis: A conversation about benchmarking leading clinical chatbots, investor view on AI in biopharma, and more.STAT